alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32

Certification Pursuant to 18 U.S.C. Section 1350 as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of AXS-One Inc. (the ‘‘Company’’) on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission on the date hereof (the ‘‘Report’’), each of the undersigned officers of the Company certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002:

| |    |                                                                                                                      
| | -- | ---------------------------------------------------------------------------------------------------------------------
| | 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

| |    |                                                                                                                                                     
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------
| | 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

AXS-ONE INC.Date:    April 11, 2008


By:


/s/ William P. LyonsWilliam P. Lyons
Chairman of the Board and Chief Executive OfficerBy:


/s/ Joseph DwyerJoseph Dwyer
Executive Vice President, Chief Financial Officer,
and Treasurer


---
#### § 601.41 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.

FDA may grant marketing approval for a biological product on the basis of adequate and well-controlled clinical trials establishing that the biological product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that the applicant study the biological product further, to verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate endpoint to clinical benefit, or of the observed clinical benefit to ultimate outcome. Postmarketing studies would usually be studies already underway. When required to be conducted, such studies must also be adequate and well-controlled. The applicant shall carry out any such studies with due diligence.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S DECEMBER 31, 1995 CONDENSED FINANCIAL STATEMENTS AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                          22,603
<SECURITIES>                                         0
<RECEIVABLES>                                   38,222
<ALLOWANCES>                                     4,776
<INVENTORY>                                     11,702
<CURRENT-ASSETS>                                70,572
<PP&E>                                         145,794
<DEPRECIATION>                                  48,851
<TOTAL-ASSETS>                                 313,620
<CURRENT-LIABILITIES>                           62,503
<BONDS>                                        240,687
<COMMON>                                             4
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                      10,426
<TOTAL-LIABILITY-AND-EQUITY>                   313,620
<SALES>                                         68,551
<TOTAL-REVENUES>                               221,592
<CGS>                                           78,896
<TOTAL-COSTS>                                   78,896
<OTHER-EXPENSES>                               155,265
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              35,041
<INCOME-PRETAX>                               (48,598)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (48,598)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (48,598)
<EPS-PRIMARY>                                   (1.30)
<EPS-DILUTED>                                   (1.30)
        

</TABLE>
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S CONSOLIDATED FINANCIAL STATEMENTS OF INCOME AND CONSOLIDATED BALANCE
SHEETS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          MAR-31-1999
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               DEC-26-1998
<CASH>                                          35,080
<SECURITIES>                                     3,509
<RECEIVABLES>                                  103,770
<ALLOWANCES>                                     3,872
<INVENTORY>                                    105,691
<CURRENT-ASSETS>                               260,387
<PP&E>                                          15,314
<DEPRECIATION>                                   9,191
<TOTAL-ASSETS>                                 273,258
<CURRENT-LIABILITIES>                          194,519
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            10
<OTHER-SE>                                      78,729
<TOTAL-LIABILITY-AND-EQUITY>                   273,258
<SALES>                                        381,047
<TOTAL-REVENUES>                               381,047
<CGS>                                          333,482
<TOTAL-COSTS>                                  333,482
<OTHER-EXPENSES>                                30,659
<LOSS-PROVISION>                                  (59)
<INTEREST-EXPENSE>                                 221
<INCOME-PRETAX>                                 17,712
<INCOME-TAX>                                     6,908
<INCOME-CONTINUING>                             10,804
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    10,804
<EPS-PRIMARY>                                     1.28
<EPS-DILUTED>                                     1.25
        

</TABLE>
**BF** IN THE SUPREME COURT OF THE STATE OF MONTANA No. DA 19 - 00 65 STATE OF MONTANA,

Plaintiff and Appellee , v. VINCENT SCOTT PARKER ,

Defendant and Appellant .

**ORDER** Upon consideration of Appellee’s motion for a 6 0 - day extension of time, and good cause appearing therefor, IS IT HEREBY ORDERED that Appellee is granted an extension of time to and including June 8 , 2020 , within which to prepare, serve, and file its response brief

.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

April 3 2020

04/03/2020

Case Number: DA 19-0065
EXHIBIT
32.2




SECTION
906 CERTIFICATION OF C.F.O.






CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT


TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002






In
connection with the Quarterly Report on Form 10-Q of Lifeway Foods, Inc. (the
“Company”) for the period ended March 31, 2009 as filed with the SEC (the
“Report”), the undersigned, in the capacity and on the date indicated below,
hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that to his
knowledge:




1.
            The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and





2.
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operation of the
      Company.








Date:
                May
      15, 2009
                
                By:
                /s/
      Edward P. SmolyanskyEdward
      P. Smolyansky
                  Chief
      Financial  and Accounting Officer and Treasurer
(logo)Rialto 

         CAPITAL

 

 

**2017 AnnualStatement of Servicer Compliance (Item 1123)**

 

Pooling and Servicing Agreement (the“Pooling and Servicing Agreement”) dated as of August 1, 2015 by and amongWells Fargo Commercial Mortgage Securities, Inc., as Depositor, Wells FargoBank, National Association as Master Servicer, Rialto Capital Advisors, LLC asSpecial Servicer, TriMont Real Estate Advisors, Inc. as Trust Advisor, WellsFargo Bank, National Association as Certificate Administrator, as TaxAdministrator and as Custodian, and Wilmington Trust, National Association asTrustee relating to the Wells Fargo Commercial Mortgage Trust 2015-SG1,Commercial Mortgage Pass-Through Certificates, Series 2015-SG1 (**WFCM2015-SG1**)

 

Theundersigned, a duly authorized officer of Rialto Capital Advisors, LLC, asspecial servicer (the “Special Servicer”) herein certifies to the following:

 

1.      Allservicing activities and performance of such servicing activities under thePooling and Servicing Agreement are performed on behalf of the SpecialServicer.

 

2.      Areview of the servicing activities and performance by the Special Servicer forthe period of January 1, 2017 to December 31, 2017 (the “Reporting Period”) inaccordance with the Pooling and Servicing Agreement has been conducted under mysupervision.

 

3.      To thebest of my knowledge, based on such review, the Special Servicer has fulfilledall of its obligations under the terms of the Pooling and Servicing Agreement,in all material respects for the Reporting Period and if there has been afailure to fulfill any such obligations in any material respect, each failureand the nature and status thereof has been specifically identified herein.

 

 

Certifiedby: /s/ Adam Singer

AdamSinger, Managing Director

 

Date:March 1, 2018
<PAGE>



                                                                   Exhibit 10.70

                    [ENGLISH SUMMARY OF THE HEBREW ORIGINAL]


                    AGREEMENT OF LEASE DATED DECEMBER 6, 2000
                                     BETWEEN
                               JANET NISSIM ET AL.
                                       AND
                          M.D.T. PROTECTIVE (2000) LTD.


     Summary of a Rental Agreement made and entered into in Jerusalem on the 6th
day of December  2000 between  Janet Nissim and Moshe Plomo (the  "Lessor")  and
M.D.T Protective (2000) Ltd. (the "Lessee").

     1. Demised Premises. 1,150 square meters zoned for industrial, workshop and
storage use from the Israel Lands  Authority  according to the agreement  signed
with them on June 3, 1991, as outlined in appendix A.

     2. Rental Period.  The rental period will be for a period of two years from
March 6, 2001 until March 5, 2003 in accordance  with the  conditions set out in
the  agreement.  The Lessee has the right to extend the rental  period under the
same  conditions for an additional  two years,  which will  automatically  renew
unless the Lessee sends a letter in writing to the Lessor 60 days before the end
of the lease to cancel.

     3. Rent. The rent for the  contractual  period will be $4,500 in equivalent
New Israeli Shekels plus VAT per month, of which three months rent is payable in
advance.

     4.  Renovations,  Etc. The Lessor will be responsible for basic renovations
in infrastructure  such as sewage systems,  water, and electricity.  Lessor pays
all purchase tax and/or any other taxes that are the legal responsibility of the
owner.  The Lessee pays all other taxes and all local  authority fees during the
rental period.  The Lessor pays for the day-to-day upkeep of the building,  such
as  water  according  to  the  meter  and  according  to  the  industrial  rate,
electricity, etc., and will give copies to the Lessee for reimbursement.

     5.  Security  Deposit.  The Lessee will provide the Lessor with a letter of
guarantee for $5,000,which will be held in escrow by Adv. Daniel Azriel and will
not be used prior to a warning period of 15 days from the day of the breach.

     6.  Miscellaneous.  All  correspondence  will be sent by  registered  mail,
according to the addresses  set out in this contract  above and will be used for
all legal transaction,  warning,  or warning or request which could arise out of
this contract. Each side pays its own legal fees.
<PAGE>
This disposition is not appropriate for publication and is not precedent *

except as provided by 9th Cir. R. 36-3.

The panel unanimously concludes this case is suitable for decision **

without oral argument. See Fed. R. App. P. 34(a)(2).

NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

 FOR THE NINTH CIRCUIT

EARL FELTON CRAGO, Jr.,

 Plaintiff - Appellant,

 v.

DORA B. SCHRIRO, Director of the ADC

at ADC Central Office; et al.,

 Defendants - Appellees.

No. 10-16531

D.C. No. 4:08-cv-00355-FRZ

MEMORANDUM*

Appeal from the United States District Court

for the District of Arizona

Frank R. Zapata, District Judge, Presiding

Submitted September 27, 2011** 

Before: HAWKINS, SILVERMAN, and W. FLETCHER, Circuit Judges. 

Earl Felton Crago, Jr., an Arizona state prisoner, appeals pro se from the

district court’s summary judgment in his 42 U.S.C. § 1983 action alleging that

defendants violated his Eighth Amendment rights by exposing him to unsafe levels

FILED

OCT 13 2011

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
2 10-16531

of environmental tobacco smoke (“ETS”). We have jurisdiction under 28 U.S.C.

§ 1291. We review de novo, and may affirm on any basis supported by the record.

Gordon v. Virtumundo, Inc., 575 F.3d 1040, 1047 (9th Cir. 2009). We affirm.

Summary judgment was proper because Crago failed to raise a genuine

dispute of material fact as to whether defendants disregarded an excessive risk to

his health when they instituted and enforced a smoking policy that attempted to

limit inmate exposure to ETS. See Farmer v. Brennan, 511 U.S. 825, 837 (1994)

(a prison official cannot be found liable under the Eighth Amendment unless the

official knows of and disregards an excessive risk to inmate health or safety).

The district court did not abuse its discretion by denying Crago’s motion for

appointment of counsel because Crago failed to demonstrate exceptional

circumstances. See Palmer v. Valdez, 560 F.3d 965, 970 (9th Cir. 2009) (setting

forth standard of review and requirement of “exceptional circumstances” for

appointment of counsel).

Crago’s remaining contentions are unpersuasive. 

AFFIRMED.
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Pages 10254-10255]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4699]


-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[ER-FRL-8988-6]


Environmental Impact Statements; Notice of Availability

    Responsible Agency: Office of Federal Activities, General 
Information (202) 564-1399 or http://www.epa.gov/compliance/nepa/ 
Weekly receipt of Environmental Impact Statements Filed 02/22/2010 
Through 02/26/2010 Pursuant to 40 CFR 1506.9.


[[Page 10255]]


EIS No. 20100058, Final EIS, FHWA, IN, I-69 Evansville to Indianapolis, 
Indiana Project, Section 2, Revised to Update the Stream Impacts, 
Oakland City to Washington, (IN-64 to US 50), Gibson, Pike and Daviess 
Counties, IN, Wait Period Ends: 04/05/2010, Contact: Janice Osadczuk 
317-226-7486.

EIS No. 20100059, Draft EIS, USFS, MT, East Deer Lodge Valley Landscape 
Restoration Management Project, To Conduct Landscape Restoration 
Management Activities, Pintler Ranger District, Beaverhead Deerlodge 
National Forest, Powell and Deerlodge Counties, MT, Comment Period 
Ends: 04/19/2010, Contact: Leaf Magnuson 406-683-3950.

EIS No. 20100060, Draft EIS, RUS, MN, Bemidji--Grand Rapid 230 kV 
Transmission Line Project, Propose to Construct and Operate, Beltrami, 
Hubbard, Cass, Itasca Counties, MN, Comment Period Ends: 04/19/2010, 
Contact: Stephanie Strength 202-720-0468.

EIS No. 20100061, Draft EIS, NOAA, 00, Amendment 17A to the Fishery 
Management Plan for the Snapper Grouper Fishery of the South Atlantic 
Region, To Implement Long-Term Management Measures Expected to End 
Overfishing of the Red Snapper Stock, South Atlantic Region, Comment 
Period Ends: 04/19/2010, Contact: Roy E. Crabtree 727-824-5305.

Amended Notices

EIS No. 20100045, Draft Supplement, BIA, CA, Campo Regional Landfill 
Project, Construction and Operation, Permit Lease and Sublease Use of 
Reservation Land, Campo Indian Reservation, San Diego County, CA, 
Comment Period Ends: 05/12/2010, Contact: John Rydzik 916-978-6051 
Revision to FR Notice Published 02/26/2010: Extending Comment Period 
from 04/28/2010 to 05/12/2010.

EIS No. 20100050, Draft EIS, BLM, CA, Stirling Energy Systems (SES) 
Solar 2 Project, Construct and Operate, Electric-Generating Facility, 
Imperial Valley, Imperial County, CA, Comment Period Ends: 06/23/2010, 
Contact: Erin Dreyfuss 916-978-4642 Revision to FR Notice Published 02/
26/2010: Extending Comment Period from 04/12/2010 to 06/23/2010.

EIS No. 20100051, Draft EIS, USFS, UT, South Unit Oil and Gas 
Development Project, Master Development Plan, Implementation, Duchesne/
Roosevelt Ranger District, Ashley National Forest, Duchesne County, UT, 
Comment Period Ends: 04/12/2010, Contact: David Herron 435-781-5218 
Revision to FR Notice Published 02/26/2010: Correction to Agency Code 
from USAF to USFS.


    Dated: March 2, 2010.
Robert W. Hargrove,
Director, NEPA Compliance Division, Office of Federal Activities.
[FR Doc. 2010-4699 Filed 3-4-10; 8:45 am]
BILLING CODE 6560-50-P
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THE COMPANY'S CONSOLIDATED FINANCIAL STATEMENTS OF INCOME AND CONSOLIDATED
BALANCE SHEETS
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          MAR-31-1998
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               SEP-26-1998
<CASH>                                          17,396
<SECURITIES>                                     7,218
<RECEIVABLES>                                   70,749
<ALLOWANCES>                                     3,288
<INVENTORY>                                    126,462
<CURRENT-ASSETS>                               233,046
<PP&E>                                          12,839
<DEPRECIATION>                                   7,238
<TOTAL-ASSETS>                                 247,690
<CURRENT-LIABILITIES>                          175,705
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             6
<OTHER-SE>                                      71,979
<TOTAL-LIABILITY-AND-EQUITY>                   247,690
<SALES>                                        212,864
<TOTAL-REVENUES>                               212,864
<CGS>                                          187,733
<TOTAL-COSTS>                                  187,733
<OTHER-EXPENSES>                                19,140
<LOSS-PROVISION>                                   (1)
<INTEREST-EXPENSE>                                 131
<INCOME-PRETAX>                                  6,452
<INCOME-TAX>                                     2,491
<INCOME-CONTINUING>                              3,961
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,961
<EPS-PRIMARY>                                      .70
<EPS-DILUTED>                                      .68
        

</TABLE>
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7837 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7837

 To amend the Foreign Intelligence Surveillance Act of 1978 to include 
      counternarcotics in the definition of foreign intelligence.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 29, 2024

 Ms. Houlahan (for herself, Mr. Crenshaw, Mr. Gottheimer, Mr. Ellzey, 
and Mr. Trone) introduced the following bill; which was referred to the 
  Committee on the Judiciary, and in addition to the Permanent Select 
 Committee on Intelligence, for a period to be subsequently determined 
 by the Speaker, in each case for consideration of such provisions as 
        fall within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL

 
 To amend the Foreign Intelligence Surveillance Act of 1978 to include 
      counternarcotics in the definition of foreign intelligence.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Enhancing Intelligence Collection on 
Foreign Drug Traffickers Act of 2024''.

SEC. 2. INCLUSION OF COUNTERNARCOTICS IN DEFINITION OF FOREIGN 
              INTELLIGENCE.

    Section 101(e)(1) of the Foreign Intelligence Surveillance Act of 
1978 (50 U.S.C. 1801) is amended--
            (1) in subparagraph (B), by striking ``; or'' and inserting 
        a semicolon; and
            (2) by adding at the end the following new subparagraph:
                    ``(D) international production, distribution, or 
                financing of illicit synthetic drugs, opioids, cocaine, 
                or other drugs driving overdose deaths, or precursors 
                of any aforementioned; or''.
                                 <all>
```